1 / 22

FUTURE DIRECTIONS IN OSTEOPOROSIS

FUTURE DIRECTIONS IN OSTEOPOROSIS. Sundeep Khosla, M.D. College of Medicine, Mayo Clinic. KEY CLINICAL ISSUES IN OSTEOPOROSIS. Better identification of patients in whom to use pharmacological therapy New approaches to reverse bone loss Customizing treatment: which drug(s) and when?.

lillian-gilliam
Download Presentation

FUTURE DIRECTIONS IN OSTEOPOROSIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FUTURE DIRECTIONS IN OSTEOPOROSIS Sundeep Khosla, M.D. College of Medicine, Mayo Clinic

  2. KEY CLINICAL ISSUES IN OSTEOPOROSIS • Better identification of patients in whom to use pharmacological therapy • New approaches to reverse bone loss • Customizing treatment: which drug(s) and when?

  3. KEY CLINICAL ISSUES IN OSTEOPOROSIS • Better identification of patients in whom to use pharmacological therapy • New approaches to reverse bone loss • Customizing treatment: which drug(s) and when?

  4. DUAL ENERGY X-RAY ABSORPTIOMETRY (DXA)Limitations in Assessment of Fracture Risk • Although DXA is the keystone for clinical assessment of fracture risk, epidemiologic studies and drug trials, it has some limitations • DXA measures areal BMD which overestimates true volumetric BMD, is confounded by osteophytes and extraskeletal calcification, fails to separate cortical and trabecular bone, and fails to capture important elements of bone strength • Patients with “osteopenia” constitute the largest group of all patients who fracture

  5. CURRENTLY AVAILABLE IN VIVO TECHNIQUES TO ASSESS BONE STRUCTURE • Central QCT • HRpQCT • MRI

  6. VOXEL QCT-BASED FE MODELS OF A LUMBAR VERTEBRA IN A TREATED PATIENT Keaveny et al. JBMR 21:149, 2007

  7. HRpQCT (Xtreme CT) • With a voxel size of 82 μm, can define trabecular and cortical microstructure and correlates highly with ex vivoμCT: • R ≥ 0.96 for BV/TV, Tb.N., Tb.Th., and Tb.Sp. (Laib et al. Bone 24:35, 1999); R = 0.98 for Ct.Th. (MacNeil et al. Med Eng Phys 29:1096, 2007) • Can be used to construct μFE models of bone strength (Pistoia et al. Bone 30:842, 2002)

  8. HRpQCT IMAGING (Cont’d)

  9. WRIST MRI Chesnut et al. JBMR 20:1548, 2005

  10. NOVEL IMAGING APPROACHES FOR DETERMINING OSTEOPOROSIS RISK: SUMMARY • Clearly provide important information on changes in bone structure with aging and the structural basis for fractures • While magnitude of differences between fracture and control subjects tends to be greater than with DXA, improvements in predictive ability for fracture risk are modest using current approaches • Future: • Improvements in resolution, image analysis, fidelity of FE models (eg, compression vs torsion, non-linear models) • Microstructural changes may be more relevant in the early phases of bone loss

  11. KEY CLINICAL ISSUES IN OSTEOPOROSIS • Better identification of patients in whom to use pharmacological therapy • New approaches to reverse bone loss • Customizing treatment: which drug(s) and when?

  12. EFFECT OF DIFFERENT THERAPEUTIC REGIMENS ON LUMBAR SPINE BMD IN POSTMENOPAUSAL OSTEOPORSIS 40 FS regimen 30 AR regimen high turnover 20 D BMD, % of basal 10 AR regimen low turnover 0 No treatment -10 0 1 2 3 4 Treatment, yr 1778

  13. Anti-resorptive Drugs Estrogen, SERMs Bisphosphonates Calcitonin Strontium Cathepsin K inhibitors RANKL antibody APPROVED AND PENDING DRUGS

  14. Anti-resorptive Drugs Estrogen, SERMs Bisphosphonates Calcitonin Strontium Cathepsin K inhibitors RANKL antibody Formation Stimulating Drugs Teriparatide SOST antibody Others APPROVED AND PENDING DRUGS

  15. Anti-resorptive Drugs Estrogen, SERMs Bisphosphonates Calcitonin Strontium Cathepsin K inhibitors RANKL antibody Formation Stimulating Drugs Teriparatide SOST antibody Others APPROVED AND PENDING DRUGS

  16. TERIPARATIDE • Approved at a dose of 20 μg/d for a maximum of 2 years for the treatment of postmenopausal osteoporosis/male osteoporosis/GIOP • Decreases the risk of vertebral fractures by 65% and non-vertebral fractures by 53% after an average of 18 months of therapy

  17. Anti-resorptive Drugs Estrogen, SERMs Bisphosphonates Calcitonin Strontium Cathepsin K inhibitors RANKL antibody Formation Stimulating Drugs Teriparatide SOST antibody Others APPROVED AND PENDING DRUGS

  18. WNT SIGNALING IN BONE Khosla, Westendorf, and Oursler JCI 118:421, 2008

  19. WNT SIGNALING IN BONE Khosla, Westendorf, and Oursler JCI 118:421, 2008

  20. EFFECTS OF SOST Ab ON BONE MASS AND STRUCTURE IN RATS Li et al. JBMR 24:578, 2009

  21. KEY CLINICAL ISSUES IN OSTEOPOROSIS • Better identification of patients in whom to use pharmacological therapy • New approaches to reverse bone loss • Customizing treatment: which drug(s) and when?

  22. Anti-resorptive Drugs Estrogen, SERMs Bisphosphonates Calcitonin Strontium Cathepsin K inhibitors RANKL antibody Formation Stimulating Drugs Teriparatide SOST antibody Others Which drug, when? Combinations? What sequence? Duration/drug holidays? APPROVED AND PENDING DRUGS

More Related